Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCSF for COVID-19 patients with lymphopenia
IRCT20200502047268N1Phase 2Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of granulocyte colony-stimulating factor in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Semnan University of Medical Sciences. Primary endpoint: Blood lymphocytes. Started May 2020; status: completed.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200502047268N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200502047268N1.